medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2009, Number 1

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2009; 7 (1)

Acrolentiginous melanoma associated to Parkinson disease in treatment with levodopa and carbidopa. Three cases report and a review

Pasos EA, Juárez NL

Language: Spanish
References: 15
Page: 13-17
PDF size: 156.91 Kb.


ABSTRACT

We report 3 cases of patients observed in our department with diagnosis of acrolentiginous melanoma (ALM) associated with Parkinson’s disease treated with levodopa and carbidopa. A review of the literature in relation to variant acrolentiginous melanoma —which is more common in the Latino population— has not been able to find a specific cause trigger, considering the trauma as one of the factors involved in this variety. The sickness has been associated in numerous reports to the intake of levodopa —however, recent publications show that there is an association between the development of melanoma and Parkinson’s disease rather than its treatment, based on genetic alterations recently demonstrated. During a period of 2 years in our service 7 cases were presented, calling our attention that 3 of them suffered from Parkinson’s disease treated with levodopa and carbidopa, which motivated this review.


REFERENCES

  1. Gutiérrez Vidrio RM, Cortés Lozano N. “Confrontando el melanoma en el siglo XXI”. Med Cutan Iber Am 2007; 35(1): 3-13.

  2. Tsao H, Atkins MB, Sober AJ. “Management of cutaneous melanoma”. N Eng J Med 2004; 351: 998-1012.

  3. Alfeiran Ruiz A, Escobar Alfaro G, De la Barreda Becerril F, Herrera Gómez A, Padilla Rociano A, Suchil Bernal L. “Epidemiología del melanoma de piel en México”. Rev Inst Nal Cancerol 1998; 44(3).

  4. Saldívar Moreno C, Castillero Pinilla, López Graniel C. “Melanoma acral lentiginoso”. Rev Inst Nal Cancerol 1998; 44(3).

  5. Gloster HM, Neal K. “Skin cancer in skin of color”. J Am Acad Dermatol 2006; 5(5): 741-760.

  6. Skibba J, Pinckley J, Gilbert E, Johnson R. “Multiple primary melanoma following administration of levodopa”. Arch Path 1972; 93: 556-561.

  7. Magaña M, Cazarin J, Magaña Lozano M. “Características del melano - ma en la población mexicana”. Actas de Dermatología & Dermatopato logía 2001; 1(3-4): 59-62.

  8. Johnson DS, Yamane S, Morita S, Yonehara S, Wong J. “Malignant melanoma in non-Caucasians: experience from Hawaii”. Surg Clin N Am 2003; 83: 275-282.

  9. Lieberman A, Shupack J. “Levodopa and melanoma”. Neurology 1974; 340-343.

  10. Espinoza Vera G, Poveda Ayora M. “Actualización en melanoma. Incidencia, desarrollo, aspectos biológicos y reporte de caso clínico”. Oncología 2003; 13(1-2): 88-97.

  11. Selvaag E, Larsen T, Thune P. “Melanoma and Parkinson´s disease. Letters to the editor”. Journ Eur Acad of Dermatol and Ven 1995; 5: 289- 290.

  12. Zanetti R, Loria D, Rosso S. “Melanoma, Parkinson´s disease and levodopa: causal or spurious link? A review of the literature”. Cancer Epidemiology, Biomarkers & Prevention 2006; 16: 201-206.

  13. Wick M, Kramer R, Gorman M. “Enhancement of L-Dopa incorporation into Melanoma by Dopa Decarboxylase inhibition”. J Invest Dermatol 1978; 70: 358-260.

  14. Kannengiesser C, Dalle S, Leccia M, Avril M, Bonadona V, Chompret A, Lasset C, Leroux D, Thomas L, Lesuerur F, Lenoir G, Sarasin A, Laillerets B. “New founder germline mitation of CDKN2A in melanoma-prone families and multiple primary melanoma development in a patient receiving levodopa treatment”. Genes, Chromosomes & Cancer 2007; 46: 751-760.

  15. Fermaglich J. “Melanoma and Parkinson Disease”. Neurology 1978; 404. Volumen




2020     |     www.medigraphic.com